Takeda Pharmaceutical Co Ltd's Form 4 filing
Phathom Pharmaceuticals, Inc. (PHAT) · filed Nov 8, 2021
- Accession no.
- 0001395064-21-000231
- Filed
- Nov 8, 2021
- Trade date
- Nov 4, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $20.9M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Takeda Pharmaceutical Co LtdCIK 0001395064 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 4, 2021 | Common Stock | XIn-the-money exerciseAcquired | +228,696 | $0.00F1 | $0 | 1,100,001 | Direct | |
| Nov 4, 2021 | Common Stock | SSaleDisposed | −1 | $19.00 | −$19 | 1,100,000 | Direct | |
| Nov 4, 2021 | Common Stock | SSaleDisposed | −1,000,000 | $20.85 | −$20,850,000 | 100,000 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 4, 2021 | Common Stock | XIn-the-money exerciseDisposed | −228,696 | $0.00 | $0 | 7,359,304 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On November 4, 2021, the Reporting Person exercised a Warrant to purchase 228,696 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $8.45 in lieu of a fractional share.
Referenced by the price of 1 transaction in Table I.